NCT02904954View on ClinicalTrials.gov

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 2, 2016

Primary Completion Date

September 16, 2020

Study Completion Date

October 4, 2022

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Durvalumab

Intravenously

OTHER

Durvalumab plus SBRT

Intravenously plus radiotherapy

Trial Locations (1)

10065

Weill Cornell Medicine, New York

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER